11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID
- Product Name
- 11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID
- CAS No.
- 571186-50-0
- Chemical Name
- 11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID
- Synonyms
- NCX 1022;NCX-1022,NCX1022;NO-HYDROCORTISONE;Pregn-4-ene-3,20-dione, 11,17-dihydroxy-21-[[4-[(nitrooxy)methyl]benzoyl]oxy]-, (11β)-;11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID
- CBNumber
- CB6401702
- Molecular Formula
- C29H35NO9
- Formula Weight
- 541.59
- MOL File
- 571186-50-0.mol
11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID Property
- Boiling point:
- 734.2±60.0 °C(Predicted)
- Density
- 1.37±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- pka
- 12.31±0.70(Predicted)
N-Bromosuccinimide Price
- Product number
- API0003618
- Product name
- NO-HYDROCORTISONE
- Purity
- 95.00%
- Packaging
- 1MG
- Price
- $560.29
- Updated
- 2021/12/16
- Product number
- API0003618
- Product name
- NO-HYDROCORTISONE
- Purity
- 95.00%
- Packaging
- 10MG
- Price
- $662.16
- Updated
- 2021/12/16
- Product number
- API0003618
- Product name
- NO-HYDROCORTISONE
- Purity
- 95.00%
- Packaging
- 50MG
- Price
- $1055.09
- Updated
- 2021/12/16
11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID Chemical Properties,Usage,Production
Uses
NCX1022 is an NO-releasing derivative of Hydrocortisone, which is the most widely used anti-inflammatory agent for the treatment of skin inflammation.
in vivo
Topical pre- and post-treatment with NCX1022 (3 nmol) in C57BL6 mice not only reduces ear oedema formation in a dose-dependent manner, but also is significantly more effective than the parent compound during the initial stages of inflammation (from 1 to 5 h). NCX1022, but not Hydrocortisone, significantly inhibits granulocyte recruitment (tissue myeloperoxidase activity). Histological samples of mouse ears treated with NCX1022 show significant reduction in both the number of infiltrated cells and disruption of the tissue architecture compared to Hydrocortisone-treated tissues. Post-treatment with Hydrocortisone does not modify the increased granulocyte infiltration induced by benzalkonium application, but NCX1022 reduces by 63% the myeloperoxidase (MPO) activity, producing a maximum effect at the dose of 3 nmol per ear. NCX1022 is significantly more potent than Hydrocortisone in reducing contact dermatitis-induced leukocyte adhesion, particularly at the early time points (e.g., 30-60 min after dermatitis induction)[1].
References
[1] Hyun E, et al. Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25. DOI:10.1038/sj.bjp.0705854
11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID Preparation Products And Raw materials
Raw materials
Preparation Products
11BETA,17,21-TRIHYDROXY-PREGN-4-ENE-3,20-DIONE METHYL ESTER 3-[(NITROOXY) METHYL]-BENZOIC ACID Suppliers
- Tel
- 010-60605840 15801484223;
- psaitong@jm-bio.com
- Country
- China
- ProdList
- 29757
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 51288865780
- sales@biosynth.com
- Country
- China
- ProdList
- 6051
- Advantage
- 58
- Tel
- 400-025-6535
- sales@adooq.cn
- Country
- China
- ProdList
- 6215
- Advantage
- 58